Datasheet: MCA6088

Product Details

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

<table>
<thead>
<tr>
<th>Application</th>
<th>Yes</th>
<th>No</th>
<th>Not Determined</th>
<th>Suggested Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELISA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species

Human

Product Form

Human IgG1 (kappa) antibody - liquid

Preparation

Purified IgG prepared by affinity chromatography on Protein A

Buffer Solution

Phosphate buffered saline

Preservative

Stabilisers

0.02% Proclin 300

Approx. Protein Concentrations

IgG concentration 1.0 mg/ml

Immunogen

Human TNFα

Specificity

Human Anti-TNF alpha antibody, clone D2E7 is a research grade biosimilar of the monoclonal antibody drug adalimumab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic adalimumab antibody clone D2E7.

Human Anti-TNF alpha antibody, clone D2E7 is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-adalimumab antibodies, for example HCA202 and HCA203. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-adalimumab antibody in IgG1 format as reference.
standard, for example HCA203, HCA204 or HCA205, or an anti-adalimumab antibody in IgE format as reference standard, for example HCA271.

The therapeutic antibody adalimumab (Humira) is a fully human monoclonal antibody (IgG1 kappa) approved for the treatment of ankylosing spondylitis, Crohn’s disease, psoriasis and several forms of arthritis. The antibody is specific for TNF alpha, and acts by blocking the activation of TNF receptors by TNF alpha. This inactivation down-regulates the inflammatory reactions associated with autoimmune diseases.

This product is NOT FOR THERAPEUTIC USE.

View a summary of supporting anti-adalimumab antibody products

<table>
<thead>
<tr>
<th>Purity</th>
<th>&gt;98% by SDS PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use</td>
</tr>
<tr>
<td>Guarantee</td>
<td>12 months from date of despatch</td>
</tr>
<tr>
<td>Licensed Use</td>
<td>For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.</td>
</tr>
<tr>
<td>Regulatory</td>
<td>For research purposes only</td>
</tr>
</tbody>
</table>

## Related Products

### Recommended Useful Reagents

- HUMAN ANTI ADALIMUMAB (HCA202)
- HUMAN ANTI ADALIMUMAB (HCA203)
- HUMAN ANTI ADALIMUMAB (HCA204)
- HUMAN ANTI ADALIMUMAB:HRP (HCA204P)
- HUMAN ANTI ADALIMUMAB (HCA205)
- HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA206)
- HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA207)
- HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA231)
- HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX) (HCA232)
- HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX):HRP (HCA232P)
- HUMAN ANTI ADALIMUMAB (HCA271)
- HISPEC ASSAY DILUENT (BUF049A)
- LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK001P)